Veracyte, Inc. (VCYT) fundamentals score
At Veracyte, it believes that exceptional cancer care begins with exceptional diagnostics. It is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer.
Services-Medical Laboratories · Healthcare · Listed on NASDAQ
Overall: 8.2 out of 10, Strong long-term fundamentals
- Growth: 7.2/10
- Profitability: 8.1/10
- Financial health: 9.8/10
- Earnings quality: 8.0/10
- Valuation: 7.9/10
Scores are calculated from Veracyte, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10